HUP9600766A3 - Use of calcitonin gene related peptide antagonists for the treatment of pruritus and ocular or palpebral dysaesthesias and compositions containing this compound - Google Patents
Use of calcitonin gene related peptide antagonists for the treatment of pruritus and ocular or palpebral dysaesthesias and compositions containing this compoundInfo
- Publication number
- HUP9600766A3 HUP9600766A3 HU9600766A HUP9600766A HUP9600766A3 HU P9600766 A3 HUP9600766 A3 HU P9600766A3 HU 9600766 A HU9600766 A HU 9600766A HU P9600766 A HUP9600766 A HU P9600766A HU P9600766 A3 HUP9600766 A3 HU P9600766A3
- Authority
- HU
- Hungary
- Prior art keywords
- dysaesthesias
- palpebral
- pruritus
- ocular
- compound
- Prior art date
Links
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 title 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 title 1
- 206010013886 Dysaesthesia Diseases 0.000 title 1
- 208000003251 Pruritus Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9503629A FR2732222B1 (fr) | 1995-03-28 | 1995-03-28 | Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux |
Publications (3)
Publication Number | Publication Date |
---|---|
HU9600766D0 HU9600766D0 (en) | 1996-05-28 |
HUP9600766A2 HUP9600766A2 (en) | 1997-06-30 |
HUP9600766A3 true HUP9600766A3 (en) | 1998-04-28 |
Family
ID=9477499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9600766A HUP9600766A3 (en) | 1995-03-28 | 1996-03-27 | Use of calcitonin gene related peptide antagonists for the treatment of pruritus and ocular or palpebral dysaesthesias and compositions containing this compound |
Country Status (15)
Country | Link |
---|---|
US (2) | US6169069B1 (hu) |
EP (1) | EP0734730B1 (hu) |
JP (1) | JP3024064B2 (hu) |
AR (1) | AR002975A1 (hu) |
AT (1) | ATE205089T1 (hu) |
BR (1) | BR9601461A (hu) |
CA (1) | CA2172779C (hu) |
DE (1) | DE69614907T2 (hu) |
DK (1) | DK0734730T3 (hu) |
ES (1) | ES2163596T3 (hu) |
FR (1) | FR2732222B1 (hu) |
HU (1) | HUP9600766A3 (hu) |
MX (1) | MX9601149A (hu) |
PL (1) | PL313513A1 (hu) |
RU (1) | RU2155601C2 (hu) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7081241B1 (en) * | 1998-10-06 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Extracellular rage binding protein (EN-RAGE) and uses thereof |
US7112334B2 (en) * | 2001-06-05 | 2006-09-26 | Freiberg Roberta C | Allergy inhibition |
US20040038861A1 (en) * | 2001-11-26 | 2004-02-26 | Cooper Garth J. S. | Methods and compositions for normalizing lipid levels in mammalian tissues |
US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
PL2380592T3 (pl) | 2005-11-14 | 2018-07-31 | Teva Pharmaceuticals International Gmbh | Przeciwciało antagonistyczne skierowane przeciwko peptydowi powiązanemu z genem kalcytoniny |
BRPI0907135B8 (pt) | 2008-03-04 | 2021-05-25 | Labrys Biologics Inc | uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica |
MX2012002464A (es) | 2009-08-28 | 2012-03-14 | Rinat Neuroscience Corp | El uso de anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de la calcitonina para tratar dolor visceral. |
WO2013000917A1 (en) * | 2011-06-28 | 2013-01-03 | Bayer Intellectual Property Gmbh | Topical ophthalmological pharmaceutical composition containing regorafenib |
EP3089748A4 (en) | 2014-01-02 | 2017-09-27 | Massachusetts Eye & Ear Infirmary | Treating ocular neovascularization |
WO2015143409A1 (en) | 2014-03-21 | 2015-09-24 | Labrys Biologics, Inc. | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
BR112019005823A2 (pt) | 2016-09-23 | 2019-06-25 | Teva Pharmaceuticals Int Gmbh | tratamento para enxaqueca refratária |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9201425D0 (sv) * | 1992-05-06 | 1992-05-06 | Kabi Pharmacia Ab | Method and means for preventing constriction of the pupil in the eye |
-
1995
- 1995-03-28 FR FR9503629A patent/FR2732222B1/fr not_active Expired - Fee Related
-
1996
- 1996-03-04 DK DK96400459T patent/DK0734730T3/da active
- 1996-03-04 DE DE69614907T patent/DE69614907T2/de not_active Expired - Lifetime
- 1996-03-04 AT AT96400459T patent/ATE205089T1/de active
- 1996-03-04 ES ES96400459T patent/ES2163596T3/es not_active Expired - Lifetime
- 1996-03-04 EP EP96400459A patent/EP0734730B1/fr not_active Expired - Lifetime
- 1996-03-25 BR BR9601461A patent/BR9601461A/pt not_active Application Discontinuation
- 1996-03-27 CA CA002172779A patent/CA2172779C/fr not_active Expired - Fee Related
- 1996-03-27 MX MX9601149A patent/MX9601149A/es not_active IP Right Cessation
- 1996-03-27 PL PL96313513A patent/PL313513A1/xx unknown
- 1996-03-27 HU HU9600766A patent/HUP9600766A3/hu unknown
- 1996-03-27 AR AR10192996A patent/AR002975A1/es unknown
- 1996-03-27 JP JP8072774A patent/JP3024064B2/ja not_active Expired - Fee Related
- 1996-03-27 RU RU96105819/14A patent/RU2155601C2/ru not_active IP Right Cessation
- 1996-03-28 US US08/623,576 patent/US6169069B1/en not_active Expired - Fee Related
-
2000
- 2000-06-08 US US09/589,117 patent/US6344438B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6344438B1 (en) | 2002-02-05 |
DE69614907D1 (de) | 2001-10-11 |
BR9601461A (pt) | 1998-03-31 |
HUP9600766A2 (en) | 1997-06-30 |
DE69614907T2 (de) | 2002-01-17 |
EP0734730A1 (fr) | 1996-10-02 |
RU2155601C2 (ru) | 2000-09-10 |
US6169069B1 (en) | 2001-01-02 |
HU9600766D0 (en) | 1996-05-28 |
ES2163596T3 (es) | 2002-02-01 |
MX9601149A (es) | 1997-08-30 |
EP0734730B1 (fr) | 2001-09-05 |
DK0734730T3 (da) | 2001-12-17 |
JPH08268913A (ja) | 1996-10-15 |
PL313513A1 (en) | 1996-09-30 |
FR2732222B1 (fr) | 1997-04-25 |
ATE205089T1 (de) | 2001-09-15 |
JP3024064B2 (ja) | 2000-03-21 |
CA2172779A1 (fr) | 1996-09-29 |
AR002975A1 (es) | 1998-05-27 |
FR2732222A1 (fr) | 1996-10-04 |
CA2172779C (fr) | 2001-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA953162B (en) | Aqueous dispersion of polyurethanes which contain siloxane bridges the preparation thereof and their use as coating agents | |
IL122345A0 (en) | Benzamide derivatives their use as vasopressin antagonists processes for the preparation thereof and pharmaceutical compositions containing the same | |
AU3755900A (en) | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye | |
IL110587A (en) | Submicron emulsions for delivery of peptides | |
HUP0001442A3 (en) | Sulfonamide derivatives and pharmaceutical compositions containing them for the treatment of endothelin-mediated disorders | |
HUP0001293A3 (en) | Heterocyclic compounds and their use for inhibiting betha-amyloid peptide | |
IL135800A0 (en) | Methods and pharmaceutical compositions for the closure of retinal breaks | |
PL315653A1 (en) | Application of 4-chloro-5-(imidazolyn-2-ylamino)-6-methoxy-2-methylpyrimidine and i1 agonist as pharmaceutic agents and pharmaceutic agent as such | |
HUP9600765A3 (en) | Use of a calcitonin gene related peptide antagonists for treating skin redness of neurogenic origin, and compositions containing this compound | |
HUP9600766A2 (en) | Use of calcitonin gene related peptide antagonists for the treatment of pruritus and ocular or palpebral dysaesthesias and compositions containing this compound | |
HUP0003851A3 (en) | Pharmaceutical composition for the treatment or prevention of glomerulopathy | |
EP0750909A4 (en) | USE OF AMINO-HYDROGENATED CHINAZOLINE COMPOUNDS AND THEIR DERIVATIVES FOR BODYING IN DRUG ADDICTION | |
IL127496A0 (en) | The use of MMP inhibitors for the treatment of ocular angiogenesis | |
LT99141A (en) | Pharmaceutical compositions of tizoxanide and nitazoxanide | |
IL117620A0 (en) | Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same | |
IL117656A0 (en) | Pharmaceutical compositions for the treatment of travellers diarrhea | |
PL340305A1 (en) | Composition of agents reducing the level of lipoides | |
IL107323A (en) | Pharmaceutical compositions containing 5-(N-heterosubstituted amino) quinolones and several such new compounds | |
HUP0001858A3 (en) | Bi-aromatic compounds and pharmaceutical and cosmetic compositions containing same and the use of the compounds | |
AU4797596A (en) | Use of hydrofluoroalkenes as cleaning agents, and compositions which may be used for their purpose | |
HUP9600764A3 (en) | Use of a cgrp calcitonin gene related peptide antagonists for treating lichens and pruritus, and compositions containing this compound | |
GB9413935D0 (en) | Use of maramyl peptide compounds | |
IL117655A0 (en) | Pharmaceutical compositions for the treatment of travellers diarrhea | |
AU7812794A (en) | Pharmaceutical compositions containing n-acetylcarnosine for the treatment of cataract | |
IL132516A (en) | Pharmaceutical compositions of tizoxanide and nitazoxanide |